ACT Capital Management LLC Takes Position in Replimune Group, Inc. $REPL

ACT Capital Management LLC purchased a new stake in Replimune Group, Inc. (NASDAQ:REPL) during the fourth quarter, Holdings Channel.com reports. The firm purchased 61,500 shares of the company’s stock, valued at approximately $598,000.

A number of other institutional investors and hedge funds have also made changes to their positions in REPL. International Assets Investment Management LLC purchased a new position in shares of Replimune Group in the 4th quarter valued at $29,000. Russell Investments Group Ltd. increased its holdings in shares of Replimune Group by 3,638.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock valued at $33,000 after acquiring an additional 7,569 shares during the period. CWM LLC increased its holdings in shares of Replimune Group by 248.6% in the 4th quarter. CWM LLC now owns 4,047 shares of the company’s stock valued at $39,000 after acquiring an additional 2,886 shares during the period. BNP Paribas Financial Markets increased its holdings in shares of Replimune Group by 99.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company’s stock valued at $58,000 after acquiring an additional 6,873 shares during the period. Finally, Raymond James Financial Inc. purchased a new position in shares of Replimune Group in the 2nd quarter valued at $69,000. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

Replimune Group Stock Up 13.9%

Replimune Group stock opened at $10.00 on Thursday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 5.60 and a current ratio of 5.60. The business’s 50-day simple moving average is $5.30 and its two-hundred day simple moving average is $7.25. The company has a market cap of $825.70 million, a PE ratio of -2.91 and a beta of 0.91. Replimune Group, Inc. has a fifty-two week low of $1.50 and a fifty-two week high of $13.24.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on REPL. Leerink Partners reiterated a “market perform” rating and issued a $2.00 price target (down from $11.00) on shares of Replimune Group in a report on Monday, April 13th. Weiss Ratings downgraded Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, June 3rd. Wedbush lifted their price target on Replimune Group from $2.00 to $6.00 and gave the company a “neutral” rating in a report on Monday, June 1st. HC Wainwright reiterated a “sell” rating on shares of Replimune Group in a report on Monday, April 13th. Finally, JPMorgan Chase & Co. upgraded Replimune Group from an “underweight” rating to a “neutral” rating and set a $8.00 target price on the stock in a research note on Friday, May 29th. Seven research analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus price target of $4.88.

Insiders Place Their Bets

In other Replimune Group news, insider Christopher Sarchi sold 12,000 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $9.24, for a total transaction of $110,880.00. Following the sale, the insider owned 180,962 shares in the company, valued at approximately $1,672,088.88. The trade was a 6.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 5.20% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.